Nifekalant: Difference between revisions
Appearance
Content deleted Content added
Michael7604 (talk | contribs) recategorized from Nitrobenzenes to Nitrobenzene derivatives |
removed Category:Nitrobenzene derivatives; added Category:4-Nitrophenyl compounds using HotCat |
||
Line 56: | Line 56: | ||
[[Category:Antiarrhythmic agents]] |
[[Category:Antiarrhythmic agents]] |
||
[[Category:Pyrimidines]] |
[[Category:Pyrimidines]] |
||
[[Category: |
[[Category: ]] |
||
[[Category:Potassium channel blockers]] |
[[Category:Potassium channel blockers]] |
||
Latest revision as of 10:22, 30 September 2024
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H27N5O5 |
Molar mass | 405.455 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.[1] It has the brand name Shinbit.
References
[edit]- ^ Oyabe A, Sano H (February 2002). "Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug". Nippon Yakurigaku Zasshi. 119 (2): 103–9. doi:10.1254/fpj.119.103. PMID 11862758.